Previous 10 | Next 10 |
Gainers: Ra Medical Systems (RMED) +25%, Sundial Growers (SNDL) +24%, Kindred Biosciences (KIN) +14%, Lannett (LCI) +11%, IGM Biosciences IGMS +11%.Losers: PetMed Express (PETS) -25%, SELLAS Life Sciences (SLS) -15%, Replimune REPL ...
IGM Biosciences (IGMS) expands its IgM antibody platform from oncology into infectious diseases, with the anticipated advancement of a new pipeline candidate, IGM-6268, into clinic in Q3 2021.IGM-6268 is an IgM version of an anti-SARS-CoV-2 IgG monoclonal antibody being developed as an intran...
MOUNTAIN VIEW, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS) a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the expansion of its IgM antibody platform into infectious diseases, with th...
MOUNTAIN VIEW, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside...
The following slide deck was published by IGM Biosciences, Inc. in conjunction with this event. For further details see: IGM Biosciences (IGMS) Presents At RBC Capital Markets Global Healthcare Conference
MOUNTAIN VIEW, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside...
IGM Biosciences (IGMS): Q1 GAAP EPS of -$0.95 beats by $0.02.Cash and investments of $331.67MPress Release For further details see: IGM Biosciences EPS beats by $0.02
– Recommended Phase 2 Dose of IGM-2323 Expected in 2021 – – Initial Data from Phase 1 Trial of IGM-8444 in Solid Cancers Expected in 2021 – – IND Filing for IGM-7354 Planned in 2021 – MOUNTAIN VIEW, Calif., May 06, 2021 (GL...
Urges Shareholders to Vote the WHITE Proxy Card “FOR ALL” Four of MIMEDX’s Director Nominees – Dr. Kathleen Behrens, Mr. Todd Newton, Mr. Timothy Wright, and Dr. Phyllis Gardner Entirely Reconstituted Board and New Management Team Positioned Company f...
MOUNTAIN VIEW, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a firesi...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 5.6% to $127.4 on volume of 368,729,821 shares Maxeon Solar Technologies Ltd. (MAXN) rose 14.2% to $0.2407 on volume of 294,399,898 shares Kazia Therapeutics Limited (KZIA) rose 85.6% to $1.24 on volume ...
2024-05-31 20:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-24 12:15:03 ET RBC Capital analyst issues UNDERPERFORM recommendation for IGMS on May 24, 2024 10:00AM ET. The previous analyst recommendation was Underperform. IGMS was trading at $10.01 at issue of the analyst recommendation. The overall analyst consensus : BUY...